Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07116434 · ClinicalTrials.gov registry record · NA

Discovery Diabetes

A NA study of Type 1 Diabetes, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT07116434: Recruiting NA study of Type 1 Diabetes, sponsored by Vanderbilt University Medical Center.

NCT07116434 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 150 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07116434, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if the Discovery Program can help improve diabetes management in adolescents and young adults with type 1 diabetes (T1D). The main questions it aims to answer are: Does the Discovery Program lead to better glycemic control as measured by HbA1c levels? How does participation in the Discovery Program affect diabetes distress and self-management skills? Researchers will compare participants in the Discovery Program to those receiving standard diabetes care to see if the program has a positive effect on diabetes management. Participants will: Engage in a 3-month intervention that includes personalized mobile health communications and clinician support. Complete surveys and assessments at the beginning of the study, and again at 3 and 6 months. Allow the study team to access their electronic health records for additional data on diabetes management.

Primary Outcome

This outcome measure will assess the change in glycemic control among participants, as indicated by changes in HbA1c levels. The primary aim is to determine whether the Discovery Program leads to significant improvements in glycemic control compared to standard diabetes care.

Conditions Studied

Interventions

  • BEHAVIORAL Discovery Program

Study Locations (1)

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-11-14
Est. Completion 2027-11
Phase NA

What NCT07116434 shows while recruiting

NCT07116434 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Discovery Program is the first listed.

NCT07116434 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT07116434 about?

NCT07116434 is a clinical study titled "Discovery Diabetes". The goal of this clinical trial is to learn if the Discovery Program can help improve diabetes management in adolescents and young adults with type 1 diabetes (T1D). The main questions it aims to answer are: Does the Discovery Program lead to better glycemic control as measured by HbA1c levels? How...

What is the current status of trial NCT07116434?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-11-14. Estimated completion is 2027-11.

What conditions does trial NCT07116434 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT07116434?

The interventions under investigation include: Discovery Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT07116434?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07116434 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07116434's enrollment target sits among peer trials

150 37th of 198 higher than 160 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07116434, the US trial registry maintained by the National Library of Medicine. NCT07116434 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.